NeuBase Therapeutics, Inc. (NBSE): Price and Financial Metrics
NBSE Price/Volume Stats
| Current price | $0.42 | 52-week high | $5.40 |
| Prev. close | $0.40 | 52-week low | $0.39 |
| Day low | $0.40 | Volume | 30,800 |
| Day high | $0.44 | Avg. volume | 213,604 |
| 50-day MA | $0.71 | Dividend yield | N/A |
| 200-day MA | $0.87 | Market Cap | 1.58M |
NBSE Stock Price Chart Interactive Chart >
NeuBase Therapeutics, Inc. (NBSE) Company Bio
NeuBase Therapeutics, Inc. produces and distributes pharmaceutical products. The Company offers drugs for the treatment of dominant genetic disorders and oncogenic mutations causing cancers. NeuBase Therapeutics serves patients in the United States.
Latest NBSE News From Around the Web
Below are the latest news stories about NEUBASE THERAPEUTICS INC that investors may wish to consider to help them evaluate NBSE as an investment opportunity.
Psychemedics Corporation Appoints Daniella Mehalik as VP - FinanceACTON, Mass., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for substance abuse, proudly announces the appointment of Daniella Mehalik as its new Vice President - Finance. In her new role, Ms. Mehalik will assume responsibility for directing and managing all financial activities at Psychemedics, including comprehensive oversight of external reporting and internal analysis. Reporting directly to CEO and President Brian Hullinger, she wil |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayIt's time to dive into the biggest pre-market stock movers as we start the trading week on Monday with the hottest coverage! |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time to start off Thursday with a breakdown of the biggest pre-market stock movers investors will want to watch this morning. |
NeuBase Therapeutics Issues Statement Regarding Filing By ShareholderPITTSBURGH, Sept. 08, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) today issued the following statement regarding the Schedule 13D filed with the U.S. Securities and Exchange Commission on August 31, 2023, by Symetryx Corporation (“Symetryx”) and their subsequent press release issued on September 6, 2023. “The NeuBase Board of Directors (“Board”) appreciates input from its shareholders. The Board remains committed to completing its comprehensive |
Why Is NeuBase Therapeutics (NBSE) Stock Down 27% Today?NeuBase Therapeutics (NBSE) stock is dropping on Thursday but that's only due to the company coming off a massive rally yesterday. |
NBSE Price Returns
| 1-mo | -59.22% |
| 3-mo | -31.47% |
| 6-mo | -40.93% |
| 1-year | -88.33% |
| 3-year | -99.65% |
| 5-year | -99.08% |
| YTD | -43.25% |
| 2023 | -80.54% |
| 2022 | -93.23% |
| 2021 | -59.80% |
| 2020 | -2.92% |
| 2019 | 300.00% |
Loading social stream, please wait...